Form 4: OptimizeRx CFO/COO Edward Stelmakh Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Edward Stelmakh, CFO/COO of OptimizeRx Corp, filed a Form 4 detailing the acquisition and disposition of common stock and restricted stock units.
Summary
- On October 3, 2024, Edward Stelmakh, CFO/COO of OptimizeRx Corp, reported changes in beneficial ownership.
- The transactions involved the conversion of 16,622 restricted stock units into common stock and the disposition of 4,177 shares to cover tax withholding obligations.
- Following these transactions, Stelmakh directly owns 27,210 shares of common stock and 16,583 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing transactions by a company executive, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and their potential impact on the market.
Key Dates
| Date | Description |
|---|---|
| 10/03/2023 | First anniversary of the grant date for restricted stock units, marking the beginning of vesting in three equal annual installments. |
| 10/03/2024 | Date of transaction involving conversion of restricted stock units and disposition of shares for tax obligations. |
| 10/07/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.